{
    "clinical_study": {
        "@rank": "158134", 
        "arm_group": [
            {
                "arm_group_label": "Group HibCY", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive Hib-MenCY-TT, Pediarix; Prevnar 13; Rotarix and Havrix."
            }, 
            {
                "arm_group_label": "Group PedHIB", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive PedvaxHIB; Pediarix; Prevnar 13; Rotarix and Havrix."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of\n      GSK Biologicals' Hib-MenCY-TT vaccine co-administered with Rotarix, Prevnar 13 and Havrix as\n      compared to PedvaxHIB co-administered with Rotarix, Prevnar 13 and Havrix in infants and\n      toddlers."
        }, 
        "brief_title": "Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neisseria Meningitidis", 
            "Haemophilus Influenzae Type b"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Haemophilus Infections", 
                "Influenza, Human"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion\n             of the investigator, can and will comply, with the requirements of the protocol.\n\n          -  A male or female between, and including, 6 and 12 weeks of age at the time of the\n             first vaccination.\n\n          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject.\n\n          -  Healthy subjects as established by medical history and clinical examination before\n             entering into the study.\n\n          -  Born full-term (i.e. born after a gestation period of at least 37 weeks inclusive).\n\n          -  Infants who have not received a previous dose of hepatitis B vaccine or those who\n             have received only 1 dose of hepatitis B vaccine administered at least 30 days prior\n             to enrollment.\n\n        Exclusion Criteria:\n\n          -  Child in care.\n\n          -  Use of any investigational or non-registered product (drug or vaccine) other than the\n             study vaccine(s) within 30 days preceding the dose of study vaccine or planned use\n             during the study period.\n\n          -  Chronic administration of immunosuppressants or other immune-modifying drugs since\n             birth prior to the first vaccine dose. Inhaled and topical steroids are allowed.\n\n          -  Previous vaccination against Neisseria meningitidis, Haemophilus influenzae type b,\n             diphtheria, tetanus, pertussis, rotavirus, pneumococcus, hepatitis A and/or\n             poliovirus; more than one previous dose of hepatitis B vaccine.\n\n          -  Planned administration/administration of a vaccine not foreseen by the study protocol\n             in the period starting 30 days before and ending 30 days after the dose of vaccines.\n             Subjects may receive inactivated influenza vaccine or pandemic influenza vaccines any\n             time during the study according to the national recommendation. Measles, mumps,\n             rubella and varicella vaccination are allowed 30 days before or 30 days after the\n             final vaccination of Hib-MenCY-TT or PedvaxHIB.\n\n          -  History of Neisseria meningitidis, Haemophilus influenzae type b, diphtheria,\n             tetanus, pertussis, pneumococcus, hepatitis B, hepatitis A, rotavirus, and/or\n             poliovirus disease.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on\n             medical history and physical examination.\n\n          -  History of allergic disease or reactions likely to be exacerbated by any component of\n             the vaccines, including dry natural latex rubber. Hypersensitivity to any component\n             of the vaccines, including gelatin or neomycin.\n\n          -  Major congenital defects or serious chronic illnesses.\n\n          -  History of any neurologic disorders or seizures. A single, simple febrile seizure is\n             allowed.\n\n          -  Subjects with history of intussusceptions or uncorrected congenital malformation of\n             the gastrointestinal tract that would predispose for intussusceptions.\n\n          -  Acute disease and/or fever at the time of enrollment.\n\n          -  Administration of immunoglobulins and/or blood products since birth or planned\n             administration during the study period."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "12 Weeks", 
            "minimum_age": "6 Weeks"
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01978093", 
            "org_study_id": "112931", 
            "secondary_id": "2013-003459-39"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group HibCY", 
                "description": "4 doses administered intramuscularly (IM) in the right upper thigh at Day 0, Month 2, Month 4 and Month 10-13.", 
                "intervention_name": "Hib-MenCY-TT vaccine (GSK792014)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Group HibCY", 
                    "Group PedHIB"
                ], 
                "description": "3 doses administered IM in the left upper thigh in HibCY Group at Day 0, Month 2 and Month 4.  2 doses administered IM in the left upper thigh at Day 0 and Month 2 and 1 dose administered IM in the right upper thigh at Month 4 in PedHIB Group.", 
                "intervention_name": "Pediarix\u00ae", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Group HibCY", 
                    "Group PedHIB"
                ], 
                "description": "2 doses administered orally at Day 0 and Month 2.", 
                "intervention_name": "Rotarix\u00ae", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Group HibCY", 
                    "Group PedHIB"
                ], 
                "description": "4 doses administered IM in the left lower thigh at Day 0, Month 2, Month 4 and Month 10-13.", 
                "intervention_name": "Prevnar 13\u00ae", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group PedHIB", 
                "description": "3 doses administered IM in the right upper thigh at Day 0, Month 2 and Month 10-13.", 
                "intervention_name": "PedvaxHIB\u00ae", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Group HibCY", 
                    "Group PedHIB"
                ], 
                "description": "2 doses administered IM in the left upper thigh at Month 10-13 and Month 16-19.", 
                "intervention_name": "Havrix\u00ae", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Conjugate", 
            "Immunogenicity", 
            "Hib-MenCY-TT vaccine", 
            "Haemophilus type b", 
            "Safety", 
            "Reactogenicity"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35235"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Fayetteville", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72703"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Jonesboro", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72401"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Fresno", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93726"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Huntington Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92647"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94611"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Paramount", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90723"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Pleasanton", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94588"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Roseville", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95661"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95823"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "San Jose", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95119"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Santa Clara", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95051"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Walnut Creek", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94596"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Fall River", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02724"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Woburn", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01801"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Niles", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49120"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Stevensville", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49127"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27609"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44121"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Dayton", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45406"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Hermitage", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16148"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29406"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Layton", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84041"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Murray", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84124"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Orem", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84057"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Roy", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84067"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Syracuse", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84075"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Hib-MenCY-TT Vaccine 792014 Compared to Merck & Co, Inc. Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) Vaccine in Healthy Infants and Toddlers", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Immunogenicity with respect to components of Hib-MenCY-TT and PedvaxHIB in terms of antibody concentrations", 
                "safety_issue": "No", 
                "time_frame": "1 month after the fourth dose (in HibCY Group) or 1 month after third dose (in PedHIB Group)"
            }, 
            {
                "measure": "Immunogenicity with respect to the components of Rotarix in terms of antibody concentrations", 
                "safety_issue": "No", 
                "time_frame": "2 months post-dose 2 of Rotarix"
            }, 
            {
                "measure": "Immunogenicity with respect to the components of Havrix in terms of antibody concentrations", 
                "safety_issue": "No", 
                "time_frame": "1 month post-dose 2 of Havrix"
            }, 
            {
                "measure": "Immunogenicity with respect to the components of Prevnar 13 in terms of antibody concentrations", 
                "safety_issue": "No", 
                "time_frame": "1 month post-dose 3 of Prevnar 13"
            }, 
            {
                "measure": "Immunogenicity with respect to the components of Prevnar 13 in terms of antibody concentrations", 
                "safety_issue": "No", 
                "time_frame": "1 month post-dose 4 of Prevnar 13"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01978093"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Immunogenicity with respect to the components of the investigational vaccine in terms of antibody concentrations", 
                "safety_issue": "No", 
                "time_frame": "2 months post-dose 2 (PedHib Group only), 1 month post-dose 3 and 1 month post-dose 4 (HibCY Group only)"
            }, 
            {
                "measure": "Immunogenicity with respect to the components of the investigational vaccine in terms of antibody concentrations", 
                "safety_issue": "No", 
                "time_frame": "2 months post-dose 2 (PedHib Group only) and 1 month post-dose 3 (HibCY Group only)"
            }, 
            {
                "measure": "Immunogenicity with respect to the components of the investigational vaccine in terms of antibody titers", 
                "safety_issue": "No", 
                "time_frame": "1 month post-dose 3 and 1 month post-dose 4"
            }, 
            {
                "measure": "Immunogenicity with respect to the components of Rotarix in terms of antibody concentrations", 
                "safety_issue": "No", 
                "time_frame": "2 months post-dose 2 of Rotarix"
            }, 
            {
                "measure": "Immunogenicity with respect to the components of Havrix in terms of antibody concentrations", 
                "safety_issue": "No", 
                "time_frame": "1 month post-dose 1 of Havrix"
            }, 
            {
                "measure": "Immunogenicity with respect to the components of Havrix in terms of Geometric Mean Concentrations (GMCs)", 
                "safety_issue": "No", 
                "time_frame": "1 month post-dose 2 of Havrix"
            }, 
            {
                "measure": "Immunogenicity with respect to the components of Prevnar 13 in terms of antibody concentrations", 
                "safety_issue": "No", 
                "time_frame": "1 month post-dose 3 and 1 month post-dose 4"
            }, 
            {
                "measure": "Occurrence of solicited local and general symptoms", 
                "safety_issue": "No", 
                "time_frame": "During the 4 day (Days 0-3) follow-up period after all vaccines post-primary and post-fourth dose in the HibCY and PedHIB groups"
            }, 
            {
                "measure": "Occurrence of unsolicited adverse events", 
                "safety_issue": "No", 
                "time_frame": "During the 31-day (Days 0-30) follow-up period after all vaccines post-primary and post-fourth dose"
            }, 
            {
                "measure": "Occurrence of serious adverse events", 
                "safety_issue": "No", 
                "time_frame": "Day 0 to study end (Month 20)"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}